Efficacy of tocilizumab in refractory giant cell arteritis

Area of Science:

• Rheumatology
• Immunology
• Gastroenterology

Background:

• Giant cell arteritis (GCA) is the most common vasculitis, posing a high risk of vascular thrombosis and ischemic complications like blindness.
• Current treatments, primarily long-term corticosteroids, have significant side effects, and other immunosuppressants show limited efficacy in reducing steroid use.
• Th17 lymphocytes and interleukin-6 (IL-6) are implicated in GCA pathogenesis.

Observation:

• A rare case of refractory GCA involving the ileum (bowel) was reported in a patient dependent on high-dose steroids and methotrexate for two years.
• The patient received tocilizumab, an interleukin-6 (IL-6) blocker.

Findings:

• Tocilizumab treatment led to sustained remission of GCA symptoms for at least six months.
• The patient was able to significantly decrease corticosteroid dosage without experiencing a relapse.

Implications:

• Interleukin-6 (IL-6) blockade represents a promising therapeutic strategy for refractory giant cell arteritis (GCA), particularly cases with gastrointestinal involvement.
• Targeting the IL-6 pathway may offer an effective alternative to reduce long-term corticosteroid dependence and associated toxicities in GCA patients.
• This case highlights the potential of IL-6 inhibitors in managing complex and treatment-resistant vasculitis cases.